

BIOGEN INC.
Form 4
March 02, 2017

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2015
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
COVINO GREGORY F

(Last) (First) (Middle)

BIOGEN INC., 225 BINNEY STREET

(Street)

CAMBRIDGE, MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [BIIB]

3. Date of Earliest Transaction (Month/Day/Year)
02/28/2017

4. If Amendment, Date Original Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner
 Officer (give title below) Other (specify below)
VP, Chief Accounting Officer

6. Individual or Joint/Group Filing(Check Applicable Line)
 Form filed by One Reporting Person
 Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				(A) or (D)	Price		
Common Stock	02/28/2017 ⁽¹⁾		M	76	A \$ 0	3,988.8231	D
Common Stock	02/28/2017 ⁽¹⁾		F	25	D \$ 284.75	3,963.8231	D
Common Stock	02/28/2017 ⁽²⁾		M	163	A \$ 0	4,126.8231	D
Common Stock	02/28/2017 ⁽²⁾		F	53	D \$ 287.63	4,073.8231	D
Common Stock	02/28/2017 ⁽³⁾		M	321	A \$ 0	4,394.8231	D

Edgar Filing: BIOGEN INC. - Form 4

Common Stock	02/28/2017 ⁽³⁾	F	8	D	\$ 274.76	4,386.8231	D
Common Stock	02/28/2017 ⁽³⁾	M	121	A	\$ 0	4,507.8231	D
Common Stock	02/28/2017 ⁽³⁾	F	3	D	\$ 274.76	4,504.8231	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. F. Derivative Securities (Instr. 3 and 4)	
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	\$ 0	02/28/2017		J	143 (4)	(5) 02/12/2017	Common Stock	143	
Restricted Stock Unit	\$ 0	02/28/2017		J	131 (4)	(6) 02/22/2019	Common Stock	131	
Restricted Stock Unit	\$ 0	02/28/2017		J	128 (4)	(5) 02/23/2018	Common Stock	128	
Restricted Stock Unit	\$ 0	02/28/2017 ⁽¹⁾		M	76 (7)	(5) 02/23/2018	Common Stock	76 ⁽⁷⁾	
Restricted Stock Unit	\$ 0	02/28/2017 ⁽²⁾		M	163 (8)	(6) 02/22/2019	Common Stock	163 ⁽⁸⁾	
Restricted Stock Unit	\$ 0	02/28/2017 ⁽³⁾		M	321 (9)	(10) 02/12/2017	Common Stock	321 ⁽⁹⁾	
Restricted Stock Unit	\$ 0	02/28/2017 ⁽³⁾		M	121 (11)	(5) 02/12/2017	Common Stock	121 ⁽¹¹⁾	

Edgar Filing: BIOGEN INC. - Form 4

- (11) This award was previously reported as covering 258 shares, but was adjusted pursuant to the anti-dilution provisions of the award in connection with the spin-off of Bioverativ Inc. on February 1, 2017

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.